FGFR2 and cholangiocarcinoma: Goyal et al. reported that FGFR inhibitors have distinct activity profiles against secondary FGFR2 kinase mutations in intrahepatic cholangiocarcinoma cell lines, and that futibatinib was active against multiple FGFR2 mutations conferring resistance to infigratinib or Debio 134761.